ArticleBlood2010
A recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapy.
Article in Blood, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 28 citations in OpenAlex.
- Increased CD59 protein expression is associated with the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP.Medical oncology (Northwood, London, England) · 2014Trial
- The multiverse of CD46 and oncologic interactions.The Journal of clinical investigation · 2025Review
- CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells.Cancer biology & therapy · 2024Article
- Nanobody-mediated complement activation to kill HIV-infected cells.EMBO molecular medicine · 2023Article
- Membrane cofactor protein (MCP; CD46): deficiency states and pathogen connections.Current opinion in immunology · 2021Review
- Herbal NF-κB Inhibitors Sensitize Rituximab-Resistant B Lymphoma Cells to Complement-Mediated Cytolysis.Frontiers in oncology · 2021Article
- CD59 Regulation by SOX2 Is Required for Epithelial Cancer Stem Cells to Evade Complement Surveillance.Stem cell reports · 2017Article
- The dual role of complement in cancer and its implication in anti-tumor therapy.Annals of translational medicine · 2016Review
- Preclinical safety, pharmacokinetics, pharmacodynamics, and biodistribution studies with Ad35K++ protein: a novel rituximab cotherapeutic.Molecular therapy. Methods & clinical development · 2016Article
- Intracellular Signaling and Desmoglein 2 Shedding Triggered by Human Adenoviruses Ad3, Ad14, and Ad14P1.Journal of virology · 2015Article
- Recombinant Ad35 adenoviral proteins as potent modulators of human T cell activation.Immunology · 2014Article
- Protein engineering to target complement evasion in cancer.FEBS letters · 2014Review
- Enhanced antitumor immunotherapeutic effect of B-cell-based vaccine transduced with modified adenoviral vector containing type 35 fiber structures.Gene therapy · 2014Article
- Transient removal of CD46 is safe and increases B-cell depletion by rituximab in CD46 transgenic mice and macaques.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Article
- Attenuation of CD4+ T-cell function by human adenovirus type 35 is mediated by the knob protein.The Journal of general virology · 2012Article
- Removal of the tag from His-tagged ILYd4, a human CD59 inhibitor, significantly improves its physical properties and its activity.Current pharmaceutical design · 2012Article
- Epithelial junction opener JO-1 improves monoclonal antibody therapy of cancer.Cancer research · 2011Article
- Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis.Cancer research · 2011Article
- Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14.Nature medicine · 2011Article
- A conditionally replicative adenovirus, CRAd-S-pK7, can target endometriosis with a cell-killing effect.Human reproduction (Oxford, England) · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
Abstract
Many tumors, including lymphomas, up-regulate expression of CD46 to escape destruction by complement. Tumor cells are therefore relatively resistant to therapy by monoclonal antibodies, which act through complement-dependent cytotoxicity (CDC). From an Escherichia coli expression library of adenovirus type 35 fiber knob mutants, we selected a variant (Ad35K(++)) that had a higher affinity to CD46 than did the natural Ad35 fiber knob. We demonstrated that incubation of lymphoma cells with recombinant Ad35K(++) protein resulted in transient removal of CD46 from the cell surface. Preincubation of lymphoma cells with Ad35K(++) sensitized cells to CDC, triggered by the CD20-specific monoclonal antibody rituximab. In xenograft models with human lymphoma cells, preinjection of Ad35K(++) dramatically increased the therapeutic effect of rituximab. Blood cell counts and organ histology were normal after intravenous injection of Ad35K(++) into mice that express human CD46. The presence of polyclonal anti-Ad35K(++) antibodies did not affect the ability of Ad35K(++) to enhance rituximab-mediated CDC in in vitro assays. The Ad35K(++)-based approach has potential implications in monoclonal antibody therapy of malignancies beyond the combination with rituximab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.